LEROS

Santhera Reports 2021 Annual Results

Retrieved on: 
Friday, June 10, 2022
MAA, Company, Greater, Workforce, US FDA, Prednisone, Commercial, SEAL, Review, Annual, COVID-19, Bone fracture, LR, Association, CMO, Marketing, CEST, CEO, Treasury, BST, Mass meeting, Duchenne muscular dystrophy, NDA, EGM, Annual report, Contract, Proxy, Highbridge Capital Management, DMD, Vamorolone, Patient, Congenital muscular dystrophy, LEROS, AGM, Pratteln, USD, LHON, Exercise, Cystic fibrosis, CHF, US, Program, LLC, Comment, CF, Therapy, FDA, Growth, Clinical trial, Safety, Tutoring, Cryptocurrency, Medical device, Pharmaceutical industry, Airline, Animal, Security (finance), Duchenne, Idebenone, EU

Based on the agreement with the French authorities, Santhera has supplied Raxone free of charge from August 2021 following its removal from the list of reimbursed drugs.

Key Points: 
  • Based on the agreement with the French authorities, Santhera has supplied Raxone free of charge from August 2021 following its removal from the list of reimbursed drugs.
  • In March 2021, Santhera announced promising clinical trial data from a Phase 1b trial of lonodelestat in cystic fibrosis (CF).
  • Additional details on the pipeline products and operational progress can be found in the Annual Report 2021.
  • CEO Dario Eklund, CFO Andrew Smith and CMO Dr. Shabir Hasham will discuss the 2021 financial results and comment on ongoing corporate developments.

Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress

Retrieved on: 
Friday, October 15, 2021
Program, Duchenne muscular dystrophy, Time, Lung, KEY, CHF, Vamorolone, Becker muscular dystrophy, FDA, LLC, CMD, AGM, Muscular dystrophy, CF, Caregiver, Marketing, NDA, EGM, USD, Clinical trial, Patient, Company, Neutrophil, IFRS, Maintenance, Board, BOD, EMA, LR, Goal, Financial result, Physician, Severe cognitive impairment, OF, BMD, Degenerative disease, LEROS, Steroid, Prednisone, Achievement, Growth, LHON, European Medicines Agency, Cystic fibrosis, Highbridge Capital Management, Inflammation, Annual, Review, Safety, Cryptocurrency, Hospitality industry, Animal, Pharmaceutical industry, Risk management, Dietary supplement, Security (finance), Lithium

53 LR

Key Points: 
  • 53 LR
    Cash and cash equivalents of CHF8.0 million (as of June30, 2021)
    Net revenue CHF4.5 million (H1-2020: CHF7.8 million)
    Net result for period of CHF-20.5 million (H1-2020: CHF-31.8 million)
    Pratteln, Switzerland, October15, 2021 Santhera Pharmaceuticals (SIX: SANN) announces the Companys financial results for the first half-year ended June30, 2021, and provides an update on corporate progress.
  • Already in April 2021, Santhera and ReveraGen announced new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD).
  • Based on clinical trial results, including long-term safety data up to 30 months, vamorolone at doses up to 6mg/kg/day was generally well-tolerated.
  • In June 2021, Santhera announced positive topline results from its long-term Phase 4 LEROS study with Raxone (idebenone) in the treatment of LHON.